Daniela Di Lisi il 11/09/2026

VALVE DISEASES IN CARDIAC AMYLOIDOSIS: WHAT WE HAVE TO KNOW

Curr Probl Cardiol. 2026 Sep 11:103455. doi: 10.1016/j.cpcardiol.2026.103455. Online ahead of print.ABSTRACTCardiac amyloidosis (CA) is an infiltrative cardiomyopathy caused by extracellular deposition of amyloid fibrils, most commonly derived from immunoglobulin light chains (AL) or transthyretin (

Rachel McDougall il 11/09/2026

Treatment with CFTR modulators and subsequent remission of AA amyloidosis

Clin Kidney J. 2026 Aug 18;19(9):sfag266. doi: 10.1093/ckj/sfag266. eCollection 2026 Sep.ABSTRACTCystic fibrosis transmembrane conductance regulator (CFTR) modulators have been revolutionary for cystic fibrosis patients. Their potential influence on AA amyloidosis has not been investigated. In AA am

Mario A Saporta il 10/09/2026

Guidelines for Genetic Testing of Peripheral Nerve Disorders

Muscle Nerve. 2026 Sep 9. doi: 10.1002/mus.70394. Online ahead of print.ABSTRACTInherited peripheral neuropathies (IPNs) comprise a clinically and genetically heterogeneous group of disorders affecting approximately 1 in 2500 individuals and represent one of the most common inherited neurologic dise

Valentina Allegro il 09/09/2026

Amyloidosis: Cardiac and Neurologic Involvement

Heart Fail Clin. 2026 Oct;22(4):463-475. doi: 10.1016/j.hfc.2026.07.007. Epub 2026 Aug 4.ABSTRACTThe interplay between cardiac and neurologic involvement in systemic amyloidosis is critical to understanding the full clinical burden of the disease. While cardiac involvement remains the most powerful